Syncom Formulations (India) Ltd
NSE:SYNCOMF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
S
|
Syncom Formulations (India) Ltd
NSE:SYNCOMF
|
12.7B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.4B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Syncom Formulations (India) Ltd
Glance View
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm manufactures and markets more than 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments and inhalers. Its segments include Pharmaceuticals Drugs & Formulations, Trading of Commodities and Renting of property. Its product categories include tablets, capsules, ointments, injections, liquid-oral and packaging variants. The company offers various products, including generics, alpha adrenoceptor agonist, analgesic, antipyretic, anti-inflammatory, anti-ulcer agents, antibiotic, antidepressant, antiviral, cephelo sporins, cortico steroid, estrogen, cough suppressant and sedative anticonvulsant, among others. The firm operates in more than 15 countries across the world.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Syncom Formulations (India) Ltd is 35%, which is below its 3-year median of 37.4%.
Over the last 2 years, Syncom Formulations (India) Ltd’s Gross Margin has decreased from 39.4% to 35%. During this period, it reached a low of 32.8% on Mar 31, 2025 and a high of 39.5% on Jun 30, 2024.
